Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cytokinetics Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


Net Operating Profit After Taxes (NOPAT)
The NOPAT figures display consistent negative values throughout the observed periods, indicating ongoing operational losses. The magnitude of these losses fluctuated, starting at approximately -$105.9 million in 2018, increasing slightly to about -$119.5 million in 2019. The year 2020 showed a significant improvement with losses narrowing to roughly -$31.6 million; however, this positive trend was reversed in 2021 with losses deepening markedly to around -$193.1 million, followed by a further substantial deterioration in 2022 reaching about -$460.0 million.
Cost of Capital
The cost of capital remained relatively stable over the five-year period, with minor fluctuations. Starting at 13.11% in 2018, it slightly decreased to 13.04% in 2019, then further declined to 12.27% in 2020. An uptick occurred in 2021 raising the cost to 12.95%, before slightly decreasing again to 12.29% in 2022. This stability suggests consistent expectations for required returns over this timeline.
Invested Capital
The invested capital values demonstrate high volatility and significant swings in sign, indicating potential accounting or operational anomalies. In 2018 and 2019, invested capital was negative at approximately -$78.3 million and -$106.9 million, respectively. It remained negative in 2020 at about -$88.0 million. In 2021, however, invested capital swung sharply to a positive figure of roughly $91.7 million, only to revert back to a negative value around -$117.4 million in 2022. This irregular pattern highlights considerable fluctuations in the capital base employed.
Economic Profit
The economic profit, reflecting residual income after accounting for the cost of capital, was negative in all years, mirroring the losses seen in NOPAT. The values indicate a persistent failure to generate value above cost of capital, with losses starting near -$95.6 million in 2018 and deepening to approximately -$105.6 million in 2019. There was an improvement in 2020, with a reduction in negative economic profit to about -$20.8 million. Despite this, economic profit worsened significantly in 2021 to approximately -$205.0 million and further declined in 2022 to around -$445.6 million, consistent with the NOPAT and invested capital trends.
Summary
Overall, the data reveals a pattern of sustained operational and economic losses over the five years, with a brief respite in 2020. The worsening results in 2021 and 2022 suggest increasing financial distress or investment losses. The cost of capital remained stable, indicating consistent investor expectations, while invested capital showed considerable volatility including sign reversals, which could signify structural or accounting changes. Economic profit consistently remained negative, confirming that returns were insufficient to cover the cost of capital during the entire period analyzed.

Net Operating Profit after Taxes (NOPAT)

Cytokinetics Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net loss.

4 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net loss.

7 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Loss Trend
The net loss demonstrates a consistent and significant increase over the five-year period. Beginning at approximately -106.3 million US dollars at the end of 2018, the net loss gradually worsened to -121.7 million in 2019 and further to -127.3 million in 2020. A sharper escalation is observed in 2021, with the net loss reaching approximately -215.3 million US dollars, followed by a substantial further decline to -389.0 million US dollars in 2022. This indicates increasing expenses, reduced revenues, or other factors contributing to growing financial challenges over time.
Net Operating Profit After Taxes (NOPAT) Trend
NOPAT follows a somewhat different trajectory from net loss but remains negative throughout the observed period. It starts at around -105.9 million US dollars in 2018 and deteriorates slightly to -119.5 million in 2019. In 2020, there is a notable improvement, with NOPAT improving substantially to approximately -31.6 million US dollars, indicating either a reduction in operating losses or improved operational efficiency during that year. However, this improvement is not sustained, as NOPAT declines sharply in 2021 to around -193.1 million, and further worsens to an estimated -460.0 million US dollars by the end of 2022. This sharp downturn in recent years suggests significant operational challenges impacting profitability after taxes.
Overall Financial Performance Insights
The increasing net losses alongside the fluctuating but largely negative NOPAT values suggest persistent financial difficulties with a notable deterioration in both net loss and operating profitability in the last two years of the data. The brief improvement in NOPAT in 2020 could reflect transient operational efficiencies or cost management, which were not maintained amid subsequent increases in losses. This pattern may warrant a deeper investigation into the underlying causes such as increased expenses, investments, or operational disruptions in the 2021 and 2022 periods.

Cash Operating Taxes

Cytokinetics Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The data presents a clear upward trend in cash operating taxes for the company over the observed period from December 31, 2018, to December 31, 2022. Starting at 102 thousand US dollars in 2018, the cash operating taxes increased significantly each year, peaking at 5,911 thousand US dollars by the end of 2021. However, in 2022, there was a noticeable decline to 4,236 thousand US dollars, indicating a reduction of approximately 28% from the previous year.

The absence of values for the income tax provision across all periods indicates either that such data was not reported or that there were no income tax provisions recognized during these years.

Overall, the cash operating taxes show a consistent upward trajectory with the exception of the last year, where a decline suggests possible changes in tax policy, operational conditions, or other factors impacting the tax liability related to cash operations. The lack of income tax provision data limits the ability to analyze comprehensive tax expense trends.


Invested Capital

Cytokinetics Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current portion of term loan
Short-term finance lease liabilities
Term loan, net, excluding current portion
Convertible notes, net
Long-term finance lease liabilities
Operating lease liability1
Total reported debt & leases
Stockholders’ equity (deficit)
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity (deficit)
Construction in progress6
Available-for-sale investments7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity (deficit).

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investments.


Total reported debt & leases
The total reported debt and leases show a consistent and significant upward trend over the five-year period. Beginning at $52.8 million in 2018, the figure rose sharply to $136.1 million in 2019 and remained relatively stable in 2020. From 2020 onwards, the debt level surged substantially, reaching $271.2 million in 2021 and further increasing to $751.3 million by the end of 2022. This dramatic rise in debt indicates a growing reliance on external financing or obligations over time.
Stockholders’ equity (deficit)
Stockholders’ equity exhibits considerable volatility throughout the period. Initially, it was positive at $25.9 million in 2018. However, it turned negative in 2019, reflecting a deficit of approximately $10.9 million. The position improved markedly in 2020 and 2021, reaching a peak value of $243.9 million in 2021, indicating a strong equity base during these years. Nevertheless, by the end of 2022, stockholders’ equity declined sharply into a deficit of $107.9 million, suggesting a deterioration in the company’s net asset position in the most recent year.
Invested capital
Invested capital remained negative for the majority of the analyzed period, starting at a deficit of $78.3 million in 2018 and worsening slightly to $106.9 million in 2019. There was a modest improvement in 2020, yet the figure remained negative. A notable positive shift occurred in 2021, with invested capital rising to a positive $91.7 million, implying effective investment and capital utilization during that year. This positive trend was reversed in 2022, with invested capital declining sharply back into negative territory at $117.4 million, reflecting a significant decrease in net capital invested in the company.

Cost of Capital

Cytokinetics Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cytokinetics Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The analysis of the data reveals significant fluctuations in the company's economic profit, invested capital, and economic spread ratio over the five-year period.

Economic Profit
The economic profit figures display a highly volatile and overall negative trend throughout the period examined. Initially, negative economic profit increased from -95,643 thousand USD in 2018 to -105,591 thousand USD in 2019, indicating a worsening performance. In 2020, there was a substantial improvement as the loss narrowed significantly to -20,778 thousand USD. However, this improvement was short-lived; in 2021, economic profit dramatically declined to -204,958 thousand USD, more than doubling the previous year's loss. The trend worsened further in 2022 with the economic loss reaching -445,586 thousand USD, marking the most considerable negative economic profit over the five years.
Invested Capital
The invested capital exhibits inconsistent and unusual figures, shifting between negative and positive values. In 2018 and 2019, invested capital was negative, standing at -78,273 thousand USD and -106,877 thousand USD, respectively. In 2020, the negative value decreased to -87,987 thousand USD. Notably, in 2021, there was an abrupt and significant reversal to a positive value of 91,721 thousand USD. This was followed by a return to a negative position in 2022 at -117,411 thousand USD. Such volatility and shifts in the sign of invested capital suggest potential accounting irregularities or structural changes in capital allocation.
Economic Spread Ratio
The economic spread ratio is only available for the year 2021, showing a highly negative value of -223.46%. This extreme negative ratio indicates that the return on invested capital was far below the cost of capital, reflecting substantial economic losses during that year. The absence of data for other years precludes trend analysis but the magnitude of this value supports the significant economic profit deterioration observed for 2021.

Overall, the data indicates worsening economic profitability, with particularly stark declines in recent years, coupled with unstable invested capital figures that may require further investigation. The dramatic negative economic spread ratio in 2021 underscores inefficiencies and poor capital utilization during that period.


Economic Profit Margin

Cytokinetics Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


Economic Profit
The economic profit demonstrates a volatile trend over the analyzed period. Initially, it was negative at -95,643 thousand in 2018 and worsened to -105,591 thousand in 2019. It then improved significantly in 2020 to -20,778 thousand before deteriorating sharply again in 2021 and 2022, reaching -204,958 thousand and -445,586 thousand respectively. The data indicates increasing economic losses, particularly pronounced in the last two years.
Adjusted Revenues
Adjusted revenues show significant fluctuations. In 2018 and 2019, revenues were relatively low at 31,501 thousand and 26,868 thousand, respectively. There was a substantial increase in 2020 to 142,828 thousand, followed by a decline in 2021 to 70,428 thousand, and a further sharp reduction to 7,588 thousand in 2022. This pattern indicates high variability and a declining trend in recent years.
Economic Profit Margin
The economic profit margin exhibits a highly negative profile throughout the periods, reflecting prolonged unprofitability. It started at -303.62% in 2018, worsened to -393% in 2019, improved significantly to -14.55% in 2020, but then deteriorated again to -291.02% in 2021 and dropped drastically to -5,872.24% in 2022. The extreme negative margin in 2022 highlights a severe decline in economic profitability relative to revenues.
Overall Analysis
The financial data reveals notable instability in both revenues and profitability. Despite a temporary improvement in 2020, economic losses have deepened considerably, with 2022 showing the most pronounced negative figures. The drastic drop in adjusted revenues coupled with the surge in economic losses suggests challenges in sustaining operational efficiency and profitability. This trend underscores a critical need for strategical reconsideration to address the ongoing financial decline.